Haoyou Xu

Dr. Haoyou Xu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YZYibo Zhan
Yibo Zhan
MZMin Zhao
Min Zhao
XLXiaojun Li
Xiaojun Li
HOHuiying Ouyang
Huiying Ouyang
CDChenghao Du
Chenghao Du
HXHaoyou Xu
Haoyou Xu
Objective: To report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab.Case presentation: A 42-year-old female was diagnosed with NMOSD in the first episode of the disease. Despite treatment with intravenous methylprednisolone, immunoglobulin, rituximab and immunoadsorption, together with oral steroids, azathioprine, mycophenolate mofetil and tacrolimus, she underwent various adverse events, such as abnormal liver function, repeated infections, fever, rashes, hemorrhagic shock, etc., and experienced five relapses over the ensuing four years. Finally, clinicians decided to initiate Ofatumumab to control the disease. The patient received 9 doses of Ofatumumab over the next 10 months at customized intervals. Her symptoms were stable and there was no recurrence or any adverse events.Conclusion: Ofatumumab might serve as an effective and safe alternative for NMOSD patients who are resistant to other current immunotherapies.

29 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
HOHuiying Ouyang
Huiying Ouyang
XLXiaojun Li
Xiaojun Li
HXHaoyou Xu
Haoyou Xu
YZYibo Zhan
Yibo Zhan
ZZZequan Zheng
Zequan Zheng
ZMzhao min
zhao min
Background: Pain is a common symptom in multiple sclerosis (MS), especially neuropathic pain, which has a significant impact on patients’ mental and physical health and quality of life. However, risk factors that related to neuropathic pain, still remain unclear.Objective: The study aimed to explore the risk factors of neuropathic pain among MS patients.Materials and methods: This retrospective study examined the consecutive patients diagnosed with MS in the Department of Neurology of Guangdong Provincial Hospital of Chinese Medicine between August 2011 and October 2022. Neuropathic pain was defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Demographic and clinical features were obtained from the electronic system of the hospital.Results: Our cohort revealed that the prevalence of patients with neuropathic pain in MS was 34.1%. The results indicated that the longer the spinal lesions, the greater the neuropathic pain risks (2-4: OR, 13.3(2.1-82), >5: OR, 15.2(2.7-86.8), p for tread: 0.037). Meanwhile, multivariate regression analysis showed that cervical and thoracic lesions (OR 4.276, 95% CI 1.366-13.382, P = 0.013), upper thoracic lesions (T1-T6) (OR 3.047, 95% CI 1.018-9.124, P = 0.046) were positively correlated with neuropathic pain, while basal ganglia lesions (OR 0.188, 95% CI 0.044-0.809, P = 0.025) were negatively correlated with neuropathic pain among MS patients.Conclusion: Extended spinal lesions (≥3 spinal lesions), cervical and thoracic lesions, upper thoracic lesions were independent risk factors of neuropathic pain among MS patients. Furthermore, our study found that the longer the spinal lesions, the greater the neuropathic pain risks.

1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
WZWeijun Zhang
Weijun Zhang
QHQin Huang
Qin Huang
ZXZhengzheng Xuan
Zhengzheng Xuan
SWShibiao Wu
Shibiao Wu
ZYzhao yuanqi
zhao yuanqi
HXHaoyou Xu
Haoyou Xu
Zhang W, et al. J Clin Neurol. 2020 Oct;16(4):729-730. https://doi.org/10.3988/jcn.2020.16.4.729

26 April 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
LQLulu Qin
Lulu Qin
LPLilin Peng
Lilin Peng
YSYifan Sun
Yifan Sun
GCGuixian Chen
Guixian Chen
CDChenghao Du
Chenghao Du
ZZZequan Zheng
Zequan Zheng
This study aims to explore the effects and mechanisms of Shengjiang Powder (SJP) in alleviating ischemic stroke. The middle cerebral artery occlusion and reperfusion (MCAO) model was established in rats for both the model and medication groups. Neurological function scores, TTC staining, Hematoxylin-Eosin staining and Nissl staining were employed to evaluate the preventive and therapeutic effects of SJP on MCAO in rats. Real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence double staining were used to detect the expression levels of biological markers related to the NLRP3/Caspase-1 pathway. SJP demonstrated an improvement in brain tissue damage in rats subjected to MCAO. SJP inhibited the activation of the NLRP3/Caspase-1 pathway after MCAO in rats. Caspase-1 was primarily expressed in neurons and microglia 24 h post-MCAO in rats, with minimal expression in astrocytes. SJP ameliorates brain tissue damage by inhibiting the activation of the NLRP3/Caspase-1 pathway, thereby reducing the inflammatory response and cell pyroptosis induced by MCAO in rats.

7 March 2026 in Muscle & Nerve
Verified
Journal Article
Open access
JLJing Lin
Jing Lin
GQGuoyan Qi
Guoyan Qi
SLSushan Luo
Sushan Luo
QJQilong Jiang
Qilong Jiang
BBBitao Bu
Bitao Bu
ZLZhijun Li
Zhijun Li
Introduction/Aims: Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence. The aim of this study was to assess the efficacy and safety of efgartigimod in the pediatric population. Methods: This multicenter retrospective study enrolled JMG patients (under 18 years), from 12 Chinese centers, who received at least one dose of efgartigimod. Efgartigimod was administered as weekly intravenous infusions. Study visits included W0 (baseline: pretreatment) and W1–W4 (weekly posttreatment follow‐ups). Efficacy was assessed via MG‐related Activities of Daily Living (MG‐ADL) score, Quantitative Myasthenia Gravis (QMG) score, and the MG Composite (MGC) scale. Results: Seventeen JMG patients (3 males, 14 females) with a median disease duration of 23 months were included. At W0, 88.2% of patients were classified as Myasthenia Gravis Foundation of America (MGFA) class II–V and were anti‐acetylcholine receptor (anti‐AchR) antibody positive. After efgartigimod treatment, clinically meaningful improvement (CMI) was observed in 70.6% (W1), 73% (W2), and 91.7% (W4); 66.7% achieved minimal symptom expression by W4. MG‐ADL and QMG scores decreased by 30% and 30.1% (W1) and by 87.6% and 71.8% (W4) compared to W0. No treatment‐related adverse events occurred. Discussion: Our study suggests efgartigimod is an effective therapeutic option for JMG, with favorable efficacy and safety profiles. Further studies are necessary to validate the efficacy and safety of efgartigimod in the pediatric population.

31 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
XWXiaowen Wen
Xiaowen Wen
SJShulin Jia
Shulin Jia
JWJing Wu
Jing Wu
SWSuitian Wang
Suitian Wang
TYTeng Yu
Teng Yu
HXHaoyou Xu
Haoyou Xu
Background: This study pioneers the exploration of the role of cuproptosis (a novel form of regulated cell death) in the pathogenesis of atopic dermatitis (AD). Methods: We integrated two datasets (GSE157194 and GSE193309) from the GEO database and employed weighted gene co-expression network analysis (WGCNA) to identify disease-related modules. Through multi-dimensional approaches, including differential gene expression analysis, functional enrichment analysis, GeneMANIA network construction, GSEA/GSVA pathway enrichment analysis, and immune infiltration analysis, we systematically elucidated the regulatory mechanisms of cuproptosis-related genes (CRGs) in AD. Results: The findings reveal novel mechanisms underlying AD pathogenesis. We identified 14 co-expression modules and 1173 differentially expressed genes, among which SPTLC2, AMD1, and IGSF3 were identified as key hub genes (AUC > 0.75). In-depth mechanistic analysis uncovered critical pathophysiological features of AD, including significant enrichment in chemokine signaling pathways (p < 0.001) and copper-dependent metabolic reprogramming. Notably, immune infiltration analysis demonstrated abnormal activity in 20 out of 21 immune cell types, particularly Th2 cells and macrophages, which showed strong correlations with CRG expression patterns. These findings establish an innovative “metabolic checkpoint” model for AD progression, highlighting dysregulation of the sphingolipid-immune axis as a key pathogenic mechanism. Conclusions: This study provides novel evidence, suggesting a potential link between AD and copper metabolism dysregulation, and identifies several promising targets that may aid in diagnosis and treatment. Our findings contribute to the growing understanding of AD pathogenesis and hint at possible new therapeutic directions, including copper chelation or sphingolipid-modulating approaches for difficult-to-treat AD cases. The identified CRG signatures may serve as potential biomarkers and therapeutic targets for personalized management strategies of this complex skin disorder.